On November 4, 2026 Genmab A/S (Nasdaq: GMAB) reported that 22 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 68th Annual Meeting and Exposition of the American Society of Hematology (ASH) (Free ASH Whitepaper), taking place December 12-15, 2026, in New Orleans, Louisiana, and virtually.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The breadth of data to be shared at ASH (Free ASH Whitepaper) reflects continued progress across the comprehensive epcoritamab development program, including its evaluation in earlier lines of therapy and combination regimens across multiple B-cell malignancies. Highlights include the first presentation of the primary results from the Phase 3 EPCORE DLBCL-4 study evaluating fixed duration epcoritamab plus lenalidomide in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The results from EPCORE DLBCL-4 will also be highlighted in the ASH (Free ASH Whitepaper) 2026 Press Program.
Additional presentations include updated subgroup analyses from the Phase 3 EPCORE FL-1 study evaluating epcoritamab in combination with rituximab and lenalidomide in R/R follicular lymphoma (FL), follow-up from various monotherapy and combination trials, and real-world evidence and health economic analyses that further inform the evolving clinical profile of epcoritamab.
"The range of studies accepted for presentation at this year’s American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting reflects our commitment to exploring the full utility of epcoritamab and reinforces our confidence in epcoritamab’s potential to become a core therapy across B-cell malignancies, as a monotherapy and in combination with other medicines across lines of treatment," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "Together with our partner AbbVie, we look forward to sharing these findings with the global hematology community and further exploring what they could mean for patients."
2026 R&D Update and ASH (Free ASH Whitepaper) Data Review
On December 16 at 10:30 AM EST / 4:30 PM CET, Genmab will host its 2026 R&D Update and ASH (Free ASH Whitepaper) Data Review. The event will be virtual and webcast live. Details, including the webcast link and registration will be available on www.genmab.com. This meeting is not an official program of the ASH (Free ASH Whitepaper) Annual Meeting.
All regular abstracts accepted for presentation and publication have been published and may be accessed online on the ASH (Free ASH Whitepaper) Website. Late-breaking abstracts will be posted online on Monday, December 7, 2026, at 9:00 AM EST.
The following abstracts have been accepted for presentation at ASH (Free ASH Whitepaper):
Oral Presentations
Abstract Number Abstract Title Type of Presentation Date/Time of Presentation
79* ctDNA-directed intervention with epcoritamab alone or in combination with lenalidomide and rituximab is feasible in the early post-CAR-T population at high risk of relapse: Interim results from EpLCART Oral presentation December 12, 9:30-11:00 AM (Presentation: 9:30-9:45 AM)
105 Epcoritamab plus venetoclax leads to high response rates in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): first results from Dose Cohorts 1 and 2 of the EPCORE CLL-1 trial Oral presentation December 12, 9:30-11:00 AM (Presentation: 10:00-10:15 AM)
166* A phase II trial of rituximab and epcoritamab as first-line therapy for patients with high tumor burden follicular lymphoma: Results from initial and expansion cohorts Oral presentation December 12, 12:00-1:30 PM (Presentation: 12:45-1:00 PM)
167* Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma Oral presentation December 12, 12:00-1:30 PM (Presentation: 1:00-1:15 PM)
622 Durable benefit with fixed-duration epcoritamab + polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) as 1L treatment for patients with diffuse large B-cell lymphoma: 33-month follow-up from EPCORE NHL-5 Oral presentation December 13, 12:00-1:30 PM (Presentation: 12:45-1:00 PM)
919 Epcoritamab plus lenalidomide (E-Len) compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx): Primary results from the phase 3 EPCORE DLBCL-4 study in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Oral presentation December 14, 2:45-4:15 PM (Presentation: 2:45- 3:00 PM)
*Investigator-led trial
Poster Presentations
Abstract Number Abstract Title Type of Presentation Date/Time of Presentation
1932 Efficacy and safety of epcoritamab + R-ICE in
relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Updated results from EPCORE NHL-2 Poster December 12, 5:30-7:30 PM
1933* Epcoritamab plus gemcitabine, dexamethasone, and cisplatin (Epco-GDP) demonstrates high complete response rates in relapsed/refractory large B-cell lymphoma eligible for autologous stem cell transplantation or CAR T-cell therapy: Results from a multicenter phase II investigator initiated trial Poster December 12, 5:30-7:30 PM
1957* A pilot study of epcoritamab with dose adjusted etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for treatment of newly diagnosed aggressive B-cell non-Hodgkin lymphomas: An investigator initiated trial in progress. Poster December 12, 5:30-7:30 PM
2109* Rapid tumor depletion and normalization of myeloid and lymphoid immune landscapes underlie the potent activity of the epcoritamab plus venetoclax combination in relapsed/refractory CLL after targeted therapies Poster December 12, 5:30-7:30 PM
2716 Real-world effectiveness of epcoritamab in third-line or later (3L+) settings in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Insights from Real-EPCOR Poster December 12, 5:30-7:30 PM
3516 Epcoritamab retains robust cytotoxic activity in the setting of MS4A1 5-UTR splice variant V1 with markedly reduced CD20 protein levels Poster December 13, 6:00-8:00 PM
3517 Enhanced NK-cell and T-cell-dependent mechanisms underlie the benefit of epcoritamab combination with rituximab and lenalidomide in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) Poster December 13, 6:00-8:00 PM
3519 Sustained minimal residual disease (MRD) negativity and favorable immune kinetics characterize long-term response to epcoritamab treatment in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Poster December 13, 6:00-8:00 PM
3550 Epcoritamab plus lenalidomide and rituximab (E+R2) shows a consistent safety profile and efficacy benefit over R2 in patients with relapsed or refractory follicular lymphoma (R/R FL): Updated subgroup analyses from the randomized phase 3 EPCORE FL-1 trial Poster December 13, 6:00-8:00 PM
3719* REPIFIR-AGR-GEL-23: A phase II study of epcoritamab in patients with relapsed or refractory large B-cell lymphoma in first relapse – a response-adapted approach guided by PET-CT and ctDNA-based MRD Poster December 13, 6:00-8:00 PM
4406 Cost-effectiveness of fixed-duration epcoritamab+rituximab and lenalidomide in patients with second-line or later relapsed/refractory follicular
lymphoma in the United States Poster December 13, 6:00-8:00 PM
5441* A phase II trial of epcoritamab prior to and after Anti-CD19 CAR T for relapsed or refractory large B cell lymphomas Poster December 14, 6:00-8:00 PM
5462* A prospective clinical trial of prophylactic siltuximab to prevent epcoritamab-associated cytokine release syndrome in relapsed/refractory B-cell lymphoma Poster December 14, 6:00-8:00 PM
5463 Health-related quality of life (HRQoL) in relapsed or
refractory diffuse large B-cell lymphoma (R/R DLBCL) with epcoritamab plus lenalidomide (E-Len) compared with rituximab plus gemcitabine and oxaliplatin (R-GemOx): Results of the EPCORE DLBCL-4 trial Poster December 14, 6:00-8:00 PM
*Investigator-led trial
e-Publications
Abstract Number Abstract Title Type of Presentation Date/Time of Presentation
NA Time and cost savings with fixed-duration epcoritamab + lenalidomide versus mosunetuzumab + polatuzumab for relapsed/refractory transplant- and CAR-T ineligible patients with diffuse large B-cell lymphoma Publication only NA
NA Epcoritamab for relapsed or refractory large B-cell
lymphoma in Japanese patients: interim analysis results from a real-world multicenter evaluation
(J-REALEPCO) Publication only NA
The safety and efficacy of epcoritamab have not been established for these investigational uses.
About Epcoritamab
Epcoritamab is an IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology and administered subcutaneously. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.i
Epcoritamab (approved under the brand name EPKINLY in the U.S. and Japan, and TEPKINLY in the EU) has received regulatory approval in certain lymphoma indications in more than 65 countries. Where approved, epcoritamab is a readily accessible therapy. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the relapsed or refractory (R/R) follicular lymphoma (FL) indication and additional approvals for the R/R diffuse large B-cell lymphoma (DLBCL) indication.
Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes a trial evaluating epcoritamab in combination with lenalidomide and rituximab (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information.
(Press release, Genmab, NOV 4, 2026, View Source [SID1234674215])